These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28430172)

  • 1. EZH2 alterations in follicular lymphoma: biological and clinical correlations.
    Huet S; Xerri L; Tesson B; Mareschal S; Taix S; Mescam-Mancini L; Sohier E; Carrère M; Lazarovici J; Casasnovas O; Tonon L; Boyault S; Hayette S; Haioun C; Fabiani B; Viari A; Jardin F; Salles G
    Blood Cancer J; 2017 Apr; 7(4):e555. PubMed ID: 28430172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
    Julia E; Salles G
    Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
    Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
    Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
    Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
    Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
    Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
    Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
    Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
    Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 mutations are frequent and represent an early event in follicular lymphoma.
    Bödör C; Grossmann V; Popov N; Okosun J; O'Riain C; Tan K; Marzec J; Araf S; Wang J; Lee AM; Clear A; Montoto S; Matthews J; Iqbal S; Rajnai H; Rosenwald A; Ott G; Campo E; Rimsza LM; Smeland EB; Chan WC; Braziel RM; Staudt LM; Wright G; Lister TA; Elemento O; Hills R; Gribben JG; Chelala C; Matolcsy A; Kohlmann A; Haferlach T; Gascoyne RD; Fitzgibbon J
    Blood; 2013 Oct; 122(18):3165-8. PubMed ID: 24052547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezh2 Mutations Found in the Weaver Overgrowth Syndrome Cause a Partial Loss of H3K27 Histone Methyltransferase Activity.
    Lui JC; Barnes KM; Dong L; Yue S; Graber E; Rapaport R; Dauber A; Nilsson O; Baron J
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1470-1478. PubMed ID: 29244146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
    Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
    Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
    Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
    Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
    Lue JK; Amengual JE
    Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
    Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].
    Kwiatek M; Pruchniewski Ł; Kwiatek J; Kaźmierczak M; Lewandowski K
    Wiad Lek; 2018; 71(5):1095-1098. PubMed ID: 30176648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
    Nagy Á; Bátai B; Kiss L; Gróf S; Király PA; Jóna Á; Demeter J; Sánta H; Bátai Á; Pettendi P; Szendrei T; Plander M; Körösmezey G; Alizadeh H; Kajtár B; Méhes G; Krenács L; Timár B; Csomor J; Tóth E; Schneider T; Mikala G; Matolcsy A; Alpár D; Masszi A; Bödör C
    J Intern Med; 2023 Sep; 294(3):295-313. PubMed ID: 37259686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
    Longley J; Johnson PWM
    Curr Oncol Rep; 2021 May; 23(7):76. PubMed ID: 33937922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
    Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
    Nat Med; 2016 Jun; 22(6):632-40. PubMed ID: 27135738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.